SAN FRANCISCO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer, and Hans van Houte, chief financial officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, ...

NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdegestrant (ARV-471) have been accepted for presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), taking place December 9–12, 2025 in San Antonio, Texas. Vepdegestrant is a novel investigational PROTAC estrogen receptor (ER) degrader which is being develop ...

Summary of Nurix Therapeutics Conference Call Company Overview - **Company**: Nurix Therapeutics (NasdaqGM:NRIX) - **Focus**: Targeted protein degradation, primarily in oncology and inflammation Key Points Industry and Product Development - Nurix is pioneering targeted protein degradation as a new therapeutic modality, starting with Chronic Lymphocytic Leukemia (CLL) [2][3] - The lead product, Bexobrutideg (Bexdeg), targets BTK, a validated drug target, and has shown an 80% response rate in CLL patients who have undergone four prior lines of therapy [2][3] Clinical Trials and Efficacy - Initiated pivotal trials for Bexdeg in CLL, with a focus on a triple-exposed patient population (patients treated with covalent BTK inhibitors, BCL-2 inhibitors, and non-covalent BTK inhibitors) [9][10] - The 600 mg dose of Bexdeg is expected to provide better coverage against resistance mutations and improve overall efficacy and progression-free survival [6][39] - The confirmatory phase III trial is designed to assess superiority over standard care, with a focus on global enrollment strategies [30][29] Regulatory Considerations - Discussions with the FDA regarding the appropriateness of the triple-exposed patient population for accelerated approval are ongoing, with a target follow-up duration of about one year [12][17] - The accelerated approval paradigm is under scrutiny, with Nurix confident in the unmet medical need for the triple-exposed population [13][14] Upcoming Data and Events - The upcoming ASH conference is expected to provide critical data on dose expansion and efficacy, particularly regarding duration of response and justification for the 600 mg dose [31][32] - The company aims to present data that will inform the design of the phase III trial and its relevance to the future CLL marketplace [29][32] Competitive Landscape - Bexdeg is positioned as a highly selective drug compared to competitors, with proteomics data indicating minimal off-target effects [36][38] - The company is also exploring applications in inflammation and immunology, with ongoing studies for IRAK4 and STAT6 degraders [41][52] Financial Position - Nurix has over $650 million in cash, providing a runway through the end of 2027 into 2028, which supports the launch of pivotal programs and advancement of the pipeline [55][56] Conclusion - Nurix Therapeutics is at the forefront of targeted protein degradation, with promising clinical data and a strong financial position to support its innovative therapies in oncology and inflammation. The upcoming ASH conference will be pivotal for investor insights and future developments.

Core Insights - BeyondSpring Inc. reported Q3 2025 financial results and highlighted significant clinical and corporate milestones, particularly focusing on its lead asset, Plinabulin, which is in late-stage development for cancer treatment [1][2]. Clinical Developments - Plinabulin has shown a favorable safety profile and potential as an immune-modulating therapy, with over 700 patients treated. It demonstrated an 85% disease control rate in combination with docetaxel and Keytruda for metastatic non-small cell lung cancer (NSCLC) patients who progressed after PD-1/L1 inhibitors [2][4]. - The global Phase 3 DUBLIN-3 trial results published in The Lancet Respiratory Medicine indicated that Plinabulin combined with docetaxel achieved durable survival benefits and reduced chemotherapy-induced neutropenia [2][4]. - A Phase 2 study showed a median progression-free survival (PFS) of 7.0 months and a 12-month overall survival (OS) rate of 79% for patients treated with Plinabulin, docetaxel, and pembrolizumab [5]. Financial Performance - For the nine months ended September 2025, the net loss was $6.2 million, a decrease from $6.9 million for the same period in 2024. The net loss for Q3 2025 was $1.7 million, compared to $2.2 million in Q3 2024 [7][10]. - Research and development (R&D) expenses increased to $2.9 million for the nine months ended September 2025, up from $2.2 million in the same period in 2024, primarily due to higher drug manufacturing and regulatory affairs expenses [10][17]. - General and administrative (G&A) expenses decreased to $3.4 million for the nine months ended September 2025, down from $4.9 million in 2024, attributed to lower salary expenses and professional service costs [10][17]. Corporate Milestones - SEED Therapeutics, co-founded by BeyondSpring, completed a $30 million Series A-3 financing and received IND clearance from both the US FDA and China NMPA for its lead program targeting RBM39 [4][5]. - SEED was named a finalist for the 2025 Prix Galien USA "Best Start-Up" Award, highlighting its innovative approach in the field of targeted protein degradation [4][5].

Kymera Therapeutics Conference Call Summary Company Overview - **Company**: Kymera Therapeutics (NasdaqGM:KYMR) - **Focus**: Development of a new generation of medicines using targeted protein degradation, primarily in immunology [2][3] Key Points Targeted Protein Degradation - Kymera's approach allows for the use of small amounts of drugs to completely remove disease-causing proteins, focusing on unmet medical needs [2][3] - The company is developing oral drugs with biologics-like activity, targeting previously undrugged proteins such as transcription factors (e.g., STAT6, IRF5) [3][4] Clinical Programs - **STAT6 Program (KT-621)**: - First in the clinic with potential to serve over 100 million patients globally [4] - Phase I clinical data shows effective degradation of STAT6, achieving similar pathway blockade as dupilumab, a $30 billion drug [9][18] - Phase IB study completed in atopic dermatitis, with a Phase IIB study planned for asthma in Q1 2026 [4][5] - **IRF5 Program**: - Targeting a difficult-to-drug transcription factor with strong genetic validation in diseases like lupus and rheumatoid arthritis (RA) [5][112] - Expected to enter the clinic early next year, with promising preclinical data [5][114] - **IRAK4 Program**: - Partnership with Sanofi for a second-generation degrader, with a Phase I study expected to start in 2026 [5][131] Clinical Data and Efficacy - The goal of the Phase IB study is to validate dose selection for the Phase IIB study and generate excitement in the medical community [24][26] - Safety profile in healthy volunteers was comparable to placebo, with significant biomarker modulation observed [19][21] - The company aims to demonstrate that their drug can achieve similar efficacy to dupilumab, focusing on continuous variables rather than categorical endpoints due to small sample sizes [71][76] Future Outlook - Kymera plans to initiate multiple studies, including a Phase IIB study for asthma and further development of the IRF5 program [108][135] - The company has a cash runway extending into the second half of 2028, covering ongoing studies and potential milestones from collaborations with Sanofi and Gilead [135][141] Market Position and Strategy - Kymera emphasizes the need for complete target blockade, which they believe is achievable only through their degrader technology, contrasting with small molecule inhibitors [10][12] - The company is focused on high-quality study execution and aims to provide a comprehensive understanding of their drug's safety and efficacy [89][96] Additional Insights - The competitive landscape in immunology is highlighted, with a focus on the necessity for well-tolerated oral drugs [55][76] - Kymera's strategy includes leveraging strong genetic data to support the development of their programs, particularly for IRF5 in lupus and RA [112][114] This summary encapsulates the key points discussed during the conference call, providing insights into Kymera Therapeutics' strategic direction, clinical programs, and market positioning.

Core Insights - Nurix Therapeutics, Inc. has appointed Dr. Roger Dansey to its board of directors, enhancing the company's expertise in research, drug development, and commercialization [1][2] - Dr. Dansey brings over two decades of leadership experience in hematology and oncology, having held significant roles at Pfizer and Seagen [1][2] - Nurix is focused on targeted protein degradation medicines, aiming to innovate treatment options for cancer and autoimmune diseases [3] Company Overview - Nurix Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of targeted protein degradation medicines [3] - The company's pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), with a focus on improving treatment for various cancers and autoimmune diseases [3] - Nurix's partnered drug discovery pipeline features collaborations with Gilead, Sanofi, and Pfizer, retaining options for co-development and profit sharing in the U.S. [3] Leadership and Expertise - Dr. Dansey's previous roles include Chief Development Officer and Chief Oncology Officer at Pfizer Oncology, and Chief Medical Officer at Seagen, where he contributed to the development of breakthrough cancer therapies [2] - His experience includes leadership positions at Merck, Gilead, and Amgen, where he was involved in the registration efforts for Keytruda and the development of Xgeva [2] - Dr. Dansey's appointment is expected to guide Nurix in accelerating pivotal trials for its lead asset, bexobrutideg, in chronic lymphocytic leukemia [2]

Core Insights - Nurix Therapeutics, Inc. presented new translational data from its ongoing Phase 1 study of NX-1607, a first-in-class oral inhibitor of CBL-B, at the SITC 2025 Annual Meeting, highlighting its potential in treating advanced solid tumors [1][4] Group 1: Clinical Data and Findings - The new data from the Phase 1a clinical trial showed that NX-1607 resulted in dose-dependent pharmacologic activity, leading to increased peripheral T cell activation and proliferation, particularly in patients with stable disease [2][7] - A case study of a patient with metastatic castration-resistant prostate cancer (mCRPC) indicated that treatment with NX-1607 was associated with an expansion of activated peripheral memory T cell subsets and enhanced immune activation gene signatures [3][7] - The findings suggest that NX-1607 induces peripheral immune activation linked to remodeling of the tumor microenvironment, which may contribute to local tumor control [3][7] Group 2: Mechanism and Rationale - CBL-B inhibition is supported as a novel immune-oncology therapy, with NX-1607 showing signs of immune activation and disease control in heavily pretreated patients [4][6] - The treatment demonstrated dose-dependent pharmacokinetics and pharmacodynamic modulation, confirming target engagement and inhibition of CBL-B-mediated signaling [7] - Transcriptomic analyses revealed dose-dependent enrichment of immune signaling pathways, further supporting the mechanistic link between NX-1607 exposure and immune activation [7] Group 3: Company Overview - Nurix Therapeutics is focused on developing targeted protein degradation medicines for cancer and autoimmune diseases, with a pipeline that includes inhibitors of CBL-B and Bruton's tyrosine kinase [8] - The company is advancing multiple potentially first-in-class or best-in-class therapies, leveraging a fully AI-integrated discovery engine to enhance drug development [8]

Core Insights - Prelude Therapeutics announced the publication of two abstracts featuring preclinical data on JAK2V617F mutant selective inhibitors and CALR-targeted degrader antibody conjugates, both accepted for oral presentation at the ASH 67 Annual Meeting in December 2025 [1][2] JAK2V617F Mutant Selective Inhibitors - The company has made a breakthrough in discovering the first known molecules that selectively bind to the JH2 'deep pocket' of the JAK2V617F mutation, demonstrating mutant-specific inhibition in various preclinical models of myeloproliferative neoplasms (MPNs) [2][6] - In JAK2VF-dependent mouse models, treatment with these inhibitors normalized white blood cell counts, platelet levels, and spleen size without causing cytopenias or other adverse effects, indicating their potential as disease-modifying agents [3][6] CALR-Targeted Degrader Antibody Conjugates (DACs) - The company developed a novel DAC designed to selectively bind to mutant CALR, which is present in 20-30% of MPN patients, delivering a potent CDK9 degrader payload [4][7] - The CALR x CDK9 DAC selectively eliminated CALR-mutant MPN progenitors while sparing healthy CD34+ stem cells, supporting its further development as a potential therapeutic option for CALR-mutant MPNs [4][7] Company Overview - Prelude Therapeutics is focused on developing innovative precision oncology medicines, with a pipeline that includes selective SMARCA2 and KAT6A degraders, as well as JAK2V617F mutant selective inhibitors [5] - The company aims to extend the promise of precision medicine to cancer patients in need, leveraging its expertise in targeted protein degradation to discover next-generation DACs [5]

Core Insights - Nurix Therapeutics, Inc. announced updated clinical data from the NX-5948-301 Phase 1a/1b clinical trial will be presented at the 67th American Society of Hematology Annual Meeting, focusing on treatments for chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia [1][2] Clinical Presentations - An oral presentation titled "Bexobrutideg (NX-5948), a Novel Bruton's Tyrosine Kinase (BTK) Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL)" will take place on December 6, 2025, featuring new findings [3] - A poster presentation will showcase updated results for Waldenström macroglobulinemia, highlighting the clinical activity and safety of Bexobrutideg [4] Mechanistic Insights - Nurix and collaborators will present new insights into resistance mechanisms to BTK-targeted therapies, expanding the understanding of BTK biology [2] Product Information - Bexobrutideg (NX-5948) is an investigational small molecule degrader of BTK, currently evaluated in pivotal and ongoing clinical trials for relapsed or refractory CLL and B cell malignancies [5] Company Overview - Nurix Therapeutics focuses on the discovery and development of targeted protein degradation medicines, aiming to improve treatment options for cancer and autoimmune diseases [6][7]

Foghorn Therapeutics FY Conference Call Summary Company Overview - **Company**: Foghorn Therapeutics (NasdaqGM:FHTX) - **Date of Call**: October 30, 2025 - **Focus**: Updates on proprietary programs including selective ARID1B, CBP, and EP300 degraders [1][2][3] Key Industry Insights - **Chromatin Regulatory System**: Foghorn Therapeutics targets the chromatin regulatory system, which is implicated in cancer, with mutations found in up to 50% of tumors [4][5] - **Market Opportunity**: Successful drugs targeting this biology represent multi-billion-dollar opportunities [5] Core Programs and Developments 1. **FHD-909** - **Description**: First-in-class selective oral small molecule inhibitor of SMARCA2, targeting tumors with SMARCA4 mutations [7] - **Clinical Trial**: Currently enrolling patients in a phase 1 dose escalation trial in the US and Japan, focusing on non-small cell lung cancer patients with SMARCA4 mutations [8] - **Timeline**: Anticipated decision on dose expansion by Lilly in the first half of 2026 [8] 2. **Selective ARID1B Degrader** - **Significance**: First to publicly demonstrate robust degradation of ARID1B, targeting a population with ARID1A mutations found in approximately 5% of solid tumors [9][10] - **Clinical Context**: ARID1A mutations accelerate tumor genesis and promote metastases, indicating a high unmet medical need [17] - **Progress**: Achieved 80% degradation in preclinical models, with in vivo proof of concept expected in 2026 [19][20] 3. **Selective CBP Degrader** - **Target Population**: Potential in EP300 mutated cancers and ER-positive breast cancer, with over 200,000 cases diagnosed annually in the US [24][25] - **Mechanism**: Selective degradation of CBP could provide a wider therapeutic window than dual CBP/EP300 inhibitors, avoiding hematological toxicities [24][27] - **Development Status**: Pre-development candidate CBP degrader (CPPD171) is on track for IND readiness in 2026 [10][28] 4. **Selective EP300 Degrader** - **Target Indications**: Significant potential in hematological malignancies, particularly multiple myeloma, with approximately 100,000 patients in the US potentially benefiting [31][32] - **Clinical Validation**: Previous dual CBP/EP300 inhibitors have shown compelling results in multiple myeloma, supporting the approach [34] - **Development Timeline**: Tracking towards IND-enabling studies in 2026 [38] Additional Insights - **Mechanistic Understanding**: Foghorn emphasizes a biology-first approach, focusing on novel biology and targets, with a deep mechanistic understanding of the chromatin regulatory system [5][6] - **Partnership Strategy**: The company is considering partnerships for larger tumor types, particularly in breast cancer and multiple myeloma, to leverage resources for clinical studies [80][81] - **Feedback from Conferences**: Positive feedback received on the selective degradation of ARID1B, indicating significant interest and curiosity from industry peers [83] Conclusion Foghorn Therapeutics is advancing a robust pipeline of selective degraders targeting critical components of the chromatin regulatory system, with significant potential to address unmet medical needs in various cancers. The company is on track for key milestones in 2026, including IND readiness for multiple programs.